Literature DB >> 20718757

Exogenous introduction of tissue inhibitor of metalloproteinase 2 reduces accelerated growth of TGF-β-disrupted diffuse-type gastric carcinoma.

Erik Johansson1, Akiyoshi Komuro, Caname Iwata, Akifumi Hagiwara, Yuma Fuse, Akira Watanabe, Yasuyuki Morishita, Hiroyuki Aburatani, Keiko Funa, Mitsunobu R Kano, Kohei Miyazono.   

Abstract

Diffuse-type gastric carcinoma is characterized by rapid progression and poor prognosis. High expression of transforming growth factor (TGF)-β and thick stromal fibrosis are observed in this type of gastric carcinoma. We have previously shown that disruption of TGF-β signaling via introduction of a dominant negative form of the TGF-β type II receptor (dnTβRII) into diffuse-type gastric cancer cell lines, including OCUM-2MLN, caused accelerated tumor growth through induction of tumor angiogenesis in vivo. In the present study, we show that TGF-β induces upregulation of expression of tissue inhibitor of metalloproteinase 2 (TIMP2) in the OCUM-2MLN cell line in vitro, and that expression of TIMP2 is repressed by dnTβRII expression in vivo. Transplantation of the OCUM-2MLN cells to nude mice exhibited accelerated tumor growth in response to dnTβRII expression, which was completely abolished when TIMP2 was coexpressed with dnTβRII. Although the blood vessel density of TIMP2-expressing tumors was only slightly decreased, the degree of hypoxia in tumor tissues was significantly increased and pericytes covering tumor vasculature were decreased by TIMP2 expression in OCUM-2MLN cells, suggesting that the function of tumor vasculatures was repressed by TIMP2 and consequently tumor growth was reduced. These findings provide evidence that one of the mechanisms of the increase in angiogenesis in diffuse-type gastric carcinoma is the downregulation of the anti-angiogenic protein TIMP2.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718757     DOI: 10.1111/j.1349-7006.2010.01688.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  9 in total

1.  Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Authors:  Dimitra Bourboulia; Sandra Jensen-Taubman; Matthew R Rittler; Hui Ying Han; Tania Chatterjee; Beiyang Wei; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

2.  Tissue inhibitor of metalloproteinase 2 inhibits activation of the β-catenin signaling in melanoma cells.

Authors:  Yuxuan Xia; Shaoping Wu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma.

Authors:  Bo Liang; Jun-Jie Yin; Xin-Rong Zhan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.

Authors:  Anindita Dutta; Jing Li; Carmine Fedele; Aejaz Sayeed; Amrita Singh; Shelia M Violette; Thomas D Manes; Lucia R Languino
Journal:  Biochem J       Date:  2015-03-15       Impact factor: 3.857

5.  Bone morphogenetic protein-2 and -4 play tumor suppressive roles in human diffuse-type gastric carcinoma.

Authors:  Yo-taro Shirai; Shogo Ehata; Masakazu Yashiro; Kazuyoshi Yanagihara; Kosei Hirakawa; Kohei Miyazono
Journal:  Am J Pathol       Date:  2011-10-11       Impact factor: 4.307

Review 6.  Gastric cancer stem cells: a novel therapeutic target.

Authors:  Shree Ram Singh
Journal:  Cancer Lett       Date:  2013-04-10       Impact factor: 8.679

Review 7.  Cancer stem cells: the 'heartbeat' of gastric cancer.

Authors:  Guihua Xu; Jie Shen; Xiaohui Ou Yang; Masakiyo Sasahara; Xiulan Su
Journal:  J Gastroenterol       Date:  2012-11-27       Impact factor: 7.527

Review 8.  Tumor-promoting functions of transforming growth factor-β in progression of cancer.

Authors:  Kohei Miyazono; Shogo Ehata; Daizo Koinuma
Journal:  Ups J Med Sci       Date:  2011-11-24       Impact factor: 2.384

9.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.